)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Zevra Therapeutics (ZVRA) investor relations material
Zevra Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary5 Nov, 2025
Executive summary
Q3 2025 net revenue reached $26.1 million, primarily from Miplyf/MIPLYFFA, with $22.4 million from the product and significant year-over-year growth from $3.7 million in Q3 2024.
Achieved FDA approval and commercial launch of Miplyf/MIPLYFFA for Niemann-Pick Disease Type C, with $61.0 million in sales for the nine months ended September 30, 2025.
Net loss for Q3 2025 was $0.5 million ($0.01 per share), a substantial improvement from a $33.2 million loss in Q3 2024.
Cash, cash equivalents, and investments totaled $230.4 million as of September 30, 2025, supporting strategic priorities and operational runway.
Completed sale of a rare pediatric disease priority review voucher for $148.3 million, significantly boosting net income.
Financial highlights
Q3 2025 net revenue: $26.1 million, including $22.4 million from Miplyf/MIPLYFFA, $2.4 million from French EAP, $1.2 million from Astarys royalties, and $0.1 million from Olpruva.
Revenue for the nine months ended September 30, 2025, was $72.3 million, up from $11.6 million year-over-year, driven by Miplyf/MIPLYFFA sales.
Net income for the nine months was $71.1 million, compared to a net loss of $69.8 million in the prior year period.
Operating expenses decreased to $20.4 million in Q3 2025; R&D expenses down to $3.4 million; SG&A up to $16.9 million.
Cost of product revenue was $1.2 million in Q3 2025, down from $2.3 million in Q3 2024.
Outlook and guidance
Confident in financial resources to execute strategic priorities without additional capital market needs.
Ongoing investments in Miplyf/MIPLYFFA U.S. launch, European expansion, and late-stage pipeline assets.
Management expects continued revenue growth from Miplyf/MIPLYFFA and Olpruva, with additional upside from European expansion and pipeline progress.
No major changes anticipated in selling expenses despite scaling back Apruva/OLPRUVA promotion.
Focus remains on disease awareness, patient identification, and payer coverage to drive future growth.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Zevra Therapeutics earnings date
Guggenheim Securities 2nd Annual Healthcare Innovation Conference12 Nov, 2025
Next Zevra Therapeutics earnings date
Guggenheim Securities 2nd Annual Healthcare Innovation Conference12 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Zevra Therapeutics Inc., previously known as KemPharm Inc., is a biopharmaceutical company specializing in the development of proprietary prodrugs for the treatment of serious medical conditions, with a focus on rare diseases. The company utilizes its Ligand Activated Therapy technology to create enhanced versions of FDA-approved drugs and new compounds for potential new disease indications. Zevra's product pipeline includes KP1077, designed for the treatment of idiopathic hypersomnia (IH) and narcolepsy, and KP879 for stimulant use disorder, both in Phase II clinical trials. Additionally, Zevra has FDA-approved products like AZSTARYS for attention deficit hyperactivity disorder and APADAZ, a combination treatment containing a prodrug of hydrocodone and acetaminophen. The company is headquartered in Celebration, Florida, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage